NDA 220201 · Avyxa Holdings
Favlyxa
Fluorouracil · Intravenous · Nucleoside Metabolic Inhibitor
Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Feb 20, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4,755
1,167 Phase 3, 630 recruiting
FAERS reports
77,573
73,662 serious, 10,971 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY Increased risk of serious adverse reactions or death in patients with complete DPD deficiency. Test patients for genetic variants of DPYD prior to initiating FAVLYXA unless immediate treatment is necessary. Avoid use of FAVLYXA in patients with certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency [see Warnings and Precautions (5.1) ]. WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY Increased risk of serious adverse reactions or death in patients with complete DPD deficiency. Test patients for genetic variants of DPYD prior to initiating FAVLYXA unless immediate treatment is necessary. Avoid use of FAVLYXA in patients with certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency. ( 5.1...
What it is approved for
From the label in effect Oct 23, 2026.
FAVLYXA is indicated for the treatment of patients with: FAVLYXA is a nucleoside metabolic inhibitor indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum ( 1.1 ) Adenocarcinoma of the Breast ( 1.2 ) Gastric Adenocarcinoma ( 1.3 ) Pancreatic Adenocarcinoma ( 1.4 ) 1.1 Adenocarcinoma of the Colon and Rectum 1.2 Adenocarcinoma of the Breast 1.3 Gastric Adenocarcinoma 1.4 Pancreatic Adenocarcinoma
Mechanism: Fluorouracil is a nucleoside metabolic inhibitor that interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA); these affect rapidly growing cells and may lead to cell death. Fluorouracil is converted to three main active metabolites: 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP), 5-fluorouridine-5′triphosphate (FUTP) and 5-fluoro-2′-deoxyuridine-5′-triphosphate (FdUTP). These metabolites have several effects including the inhibition of thymidylate synthase by FdUMP, incorporation of FUTP into RNA and...
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- FAVLYXA · FLUOROURACIL 2.5GM/100ML (25MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- FAVLYXA · FLUOROURACIL 250MG/10ML (25MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluorouracil" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and IIIPivotal-lookingStatus unknown
State Key Laboratory of Cancer BiologyResearch network
NCT01196260 · 8,000 participants (planned) · Start Jan 2004 · Primary completion Dec 2020
Drug: Capecitabine and Oxaliplatin · For: Colorectal Cancer
Sites: Xi'an, China
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433589 · 6,600 participants (planned) · Start Feb 2007 · Primary completion Mar 2020
Drug: anthracycline-based; docetaxel and capecitabine and 2 more · For: Breast Cancer
Sites: Amsterdam, Netherlands
- Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal CancerPivotal-lookingCompleted
Cancer Research UK, GlasgowAcademic, hospital or other
NCT00749450 · 6,088 participants · Start Mar 2008 · Primary completion Nov 2017
Drug: capecitabine; fluorouracil and 1 more · For: Colorectal Cancer
Sites: Glasgow, United Kingdom
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II EvaluationPivotal-lookingStatus unknown
Technische Universität DresdenAcademic, hospital or other
NCT04089631 · 4,812 participants (planned) · Start Jun 26, 2020 · Primary completion Jun 2023
Drug: Capecitabine · For: Colon Cancer Stage II
Sites: Dresden, Germany
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01358877 · 4,804 participants · Start Nov 8, 2011 · Primary completion Dec 19, 2016
Drug: 5-Fluorouracil; Carboplatin and 8 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Everett, California; Greenbrae, California · 546 sites in all
- Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade LesionsPivotal-lookingCompleted
AIDS Malignancy ConsortiumResearch network
NCT02135419 · 4,446 participants · Start Sep 24, 2014 · Primary completion Aug 6, 2021
Drug: imiquimod; fluorouracil · For: Anal Cancer; High-grade Squamous Intraepithelial Lesion; HIV Infection and 1 more
Sites: Los Angeles, California; Palm Springs, California; San Francisco, California · 25 sites in all
- Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryPivotal-lookingStatus unknown
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00301925 · 4,400 participants (planned) · Start Dec 16, 2005 · Primary completion Sep 2024
Drug: pegfilgrastim; capecitabine and 4 more · For: Breast Cancer
Sites: Ashford-Kent, United Kingdom; Ashington, United Kingdom; Ashton-under-Lyne, United Kingdom · 152 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea7,076
- neutropenia5,294
- nausea5,063
- vomiting4,037
- off label use3,617
- neuropathy peripheral3,541
- fatigue3,319
- disease progression3,293
- pyrexia3,085
- thrombocytopenia3,036
- febrile neutropenia2,915
- anaemia2,610
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,695 |
| 2005 | 1,687 |
| 2006 | 1,392 |
| 2007 | 1,586 |
| 2008 | 1,848 |
| 2009 | 1,815 |
| 2010 | 1,692 |
| 2011 | 2,338 |
| 2012 | 2,862 |
| 2013 | 2,240 |
| 2014 | 1,876 |
| 2015 | 2,381 |
| 2016 | 2,750 |
| 2017 | 3,197 |
| 2018 | 4,843 |
| 2019 | 5,095 |
| 2020 | 4,261 |
| 2021 | 4,265 |
| 2022 | 5,711 |
| 2023 | 6,300 |
| 2024 | 5,981 |
| 2025 | 6,681 |
| 2026 | 5,077 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE, Homann N, Pauligk C, et al. · Lancet 2019 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A, Li CP, Bodoky G, et al. · Lancet 2016 · Clinical Trial, Phase III, Multicenter Study
- Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.
Mastrantoni L, Chiaravalli M, Spring A, et al. · Lancet Oncol 2024 · Systematic Review, Comparative Study
- Comparing 5-Fluorouracil Versus Modified Carnoy's Solution for the Treatment of Odontogenic Keratocysts: A Systematic Review and Meta-Analysis.
Jacobs T, Patil D, Shanti R, et al. · J Oral Maxillofac Surg 2024 · Systematic Review, Meta-Analysis
- Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB, Mesia R, Rivera F, et al. · N Engl J Med 2008 · Clinical Trial, Phase III, Multicenter Study
- Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Conroy T, Galais MP, Raoul JL, et al. · Lancet Oncol 2014 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Avyxa Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.